Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study

ObjectivesThe antitumor activity of nivolumab plus regorafenib in colorectal cancer from a phase Ib REGONIVO study is encouraging. The present study was conducted to evaluate the efficacy and safety of regorafenib or fruquintinib plus sintilimab as third-line or above therapy in patients with micros...

Full description

Bibliographic Details
Main Authors: Caiyun Nie, Huifang Lv, Beibei Chen, Weifeng Xu, Jianzheng Wang, Yingjun Liu, Saiqi Wang, Jing Zhao, Yunduan He, Xiaobing Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
microsatellite stable
immunotherapy
targeted therapy
liver metastasis
colorectal cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.917353/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.917353/full

Similar Items